Concord Biotech Limited announced the successful completion of an ANVISA inspection by the Brazilian Health Regulatory Agency at its active pharmaceutical ingredient manufacturing facility in Limbasi. The inspection was conducted from June 8 to June 12, 2026.
The inspection covered API manufacturing operations at the Limbasi facility located in Gujarat, India. ANVISA officials reviewed the manufacturing processes, quality assurance protocols, and regulatory compliance systems at the site during the five-day review period. The inspection was concluded successfully.
The completion of the ANVISA inspection marks a regulatory milestone for Concord Biotech Limited and its API business. The approval enables Concord Biotech Limited to supply APIs directly to the Brazilian pharmaceutical market. Brazil ranks among the largest pharmaceutical markets globally by overall size and offers significant demand for API supplies.
Concord Biotech Limited operates API manufacturing facilities that supply pharmaceutical customers across multiple international markets. Concord Biotech Limited pursues regulatory approvals from health agencies across key global geographies to expand the geographic reach of its API portfolio. The broadening of regulatory clearances supports the international growth strategy for Concord Biotech's API business.
The Limbasi facility now holds ANVISA approval, adding to Concord Biotech's existing set of international regulatory clearances for API manufacturing. Concord Biotech Limited aims to increase access for its APIs across major pharmaceutical markets worldwide.
Concord Biotech Limited is listed on the National Stock Exchange of India under the symbol CONCORDBIO and on the BSE under scrip code 543960. Concord Biotech Limited communicated the completion of the inspection through a stock exchange filing on June 12, 2026.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.